Pharmaceutical brand extensions in India sit at an intersection that most legal frameworks treat separately, and the cost of that separation is borne by patients.
The notice issued by the Central Drugs Standard Control Organization on 6 July 2026, inviting comments on the use of brand name extensions by pharmaceutical companies, has been read primarily as a drug regulatory development. It is more than that. It is a moment that requires the trademark profession to examine how its tools interact with clinical reality, and to ask whether the clearance process it runs is adequate for the environment it operates in.
A consumer who buys the wrong shirt can return it. A patient who receives the wrong medicine may not get a second chance. That asymmetry is the starting point of any serious analysis of pharmaceutical naming, and it is the reason the CDSCO review deserves attention far beyond the drug approval community.
The Commercial Logic That Created the Problem
Pharmaceutical brand extensions India practitioners encounter today exist because of a commercial logic that is entirely rational from the company’s perspective and potentially dangerous from the patient’s.
A successful pharmaceutical brand carries trust that has been earned over years of prescriber relationships, patient familiarity and regulatory history. Once doctors, pharmacists and patients recognise a brand name, extending it to a new formulation, strength or therapeutic indication reduces launch costs, accelerates recall and leverages existing goodwill. A suffix added to the established name appears to solve the communication problem cleanly. The original brand communicates trust. The extension communicates difference.
The difficulty is that the suffix does not always communicate difference to the people who matter most. A prescribing doctor writing quickly, a pharmacist reading a handwritten prescription in a busy dispensary, a patient handling multiple medication strips at home, these are the real-world conditions in which pharmaceutical naming decisions have consequences. In those conditions, a suffix that looks clear on a product submission form may become invisible.
The Institutional Gap at the Centre of the Problem
The institutional structure through which pharmaceutical brand naming decisions are currently reviewed in India is divided in a way that guarantees no single participant sees the whole risk.
The trademark professional searches the Trade Marks Registry and assesses whether the proposed mark is registrable and enforceable. The drug regulator examines the product approval, the clinical data and the formulation. The marketing team tests recall among target prescribers. The prescribing doctor and the dispensing pharmacist encounter the result when it reaches the clinical setting. None of these participants is systematically required to assess whether the combined effect of the naming decision, taken as a whole, creates a foreseeable risk of medication error.
The Supreme Court in Cadila Healthcare Ltd. v. Cadila Pharmaceuticals Ltd. recognised this institutional gap and indicated that drug regulators should obtain an official search from the Trade Marks Registry before approving pharmaceutical names. The deeper problem that Cadila identified but did not resolve is that a registration search tells the regulator whether a name is legally available. It does not tell the regulator whether the name is clinically safe in the conditions under which it will actually be used.
A mark can be entirely distinctive in the trademark sense, novel on the register, and registrable without objection, while still creating a medication error risk when it is encountered by a pharmacist who is filling twenty prescriptions an hour. Legal availability and clinical safety are different questions, and the current framework answers only the first.
What a Proper Review Framework Requires
The CDSCO review offers an opportunity to design a framework that answers both questions. Based on the nature of the risk and the existing jurisprudence, a serious framework for pharmaceutical brand extensions India needs to address several elements that the current divided approval process does not systematically require.
The starting point is a combined search that goes beyond the Trade Marks Registry. Before a pharmaceutical brand extension is approved, the applicant should be required to search across trademark records, drug approval databases and databases of currently marketed medicines. The risk of confusion is not only with registered trademarks. It is with the names of medicines that are actually on pharmacy shelves, regardless of their registration status.
The framework also needs a clear test for when a single brand may be used across different active ingredients, formulations, strengths or therapeutic indications. The extension suffix model implicitly assumes that consumers, prescribers and dispensers will reliably distinguish the base brand from the extended brand in all conditions of use. That assumption should be tested rather than presumed, and the test should reflect Indian prescribing and dispensing conditions specifically, not general pharmaceutical naming standards derived from other markets.
A mandatory phonetic and visual confusion assessment is the third element any serious framework requires. The CDSCO review should require applicants to demonstrate that the proposed extension is phonetically and visually distinct from other medicines in the brand family and from other medicines in the same therapeutic category under all conditions of realistic use. This means testing the name as it will be spoken in different Indian accents, written in hurried handwriting, abbreviated on a prescription, read from a small strip packaging and encountered beside other products on a crowded pharmacy shelf.
The fourth element is a post-market surveillance mechanism with enforcement teeth. An approval framework that ends at the point of launch cannot account for the confusion incidents that only become visible after the product is in clinical use. A public system for reporting medication error incidents linked to naming confusion, combined with a regulatory power to require renaming where the evidence justifies it, is the mechanism that closes this gap.
The fifth and most fundamental element is coordination between the CDSCO and the Trade Marks Registry. Two parallel approval processes that never meet are not a framework. They are two separate frameworks with a gap between them, and the gap is where patients are harmed. Any serious review of pharmaceutical brand extensions must produce a coordinated process in which the trademark and regulatory assessments inform each other rather than proceeding independently.
The Trademark Lawyer’s Larger Role
For the trademark profession, the CDSCO review is a prompt to re-examine what pharmaceutical naming clearance should involve and what standard of advice is adequate in this specific context.
Pharmaceutical naming is not simply a clearance exercise in the ordinary trademark sense. In most product categories, a clearance opinion that confirms registrability and assesses likely confusion under the trade marks statute is sufficient for the client’s purposes. In pharmaceutical naming, it is the beginning of the inquiry, not its conclusion.
The question the trademark lawyer must answer in a pharmaceutical naming engagement is not only whether the client can obtain and enforce a registration. It is whether the proposed name remains safe when it leaves the conference room and enters clinical practice. That requires the lawyer to understand how prescriptions are written in Indian conditions, how pharmacists read and fill them, how patients handle and self-administer medicines, and how the naming architecture of the brand family as a whole interacts with the naming environment on the pharmacy shelf.
This is a more demanding instruction than standard clearance work. It may require collaboration with clinical pharmacology expertise, with pharmacy practice specialists, and with the drug approval team in a way that trademark clearance work does not typically involve. It is also the standard that the subject deserves, given the consequences when it is not met.
What the CDSCO Review Must Decide
The fundamental question the CDSCO review must answer is whether commercial convenience should permit one pharmaceutical brand to travel across unrelated formulations and active ingredients simply because an extension suffix has been added.
The case for permitting brand extensions with appropriate safeguards is real. Brand recognition genuinely reduces launch costs and accelerates patient familiarity with new medicines. An overly restrictive naming regime that prevents all extensions would impose commercial costs that would ultimately affect drug development investment and availability. The goal is not prohibition but proper management of the risk that extensions create.
The case for placing the burden squarely on the company seeking the extension is equally real, and in my view it is the stronger case. The company seeking to extend its brand carries the benefit of the existing brand equity. It should carry the burden of demonstrating that the extension does not create a foreseeable confusion risk. That burden should be discharged through the combined search, the phonetic and visual assessment, and the reasoned explanation of how the extension will be distinguished in clinical practice, all required before approval rather than investigated after a medication error has occurred.
In medicine, distinctiveness in the trademark sense is necessary but not sufficient. The name must also be safe in the specific conditions of Indian clinical practice. A framework that requires both, administered through a coordinated process that involves both the CDSCO and the Trade Marks Registry, is the outcome this review should produce.
The window for comments was short. The consequences of getting this wrong are not.
